MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
National Research Corporation Operating Income 2011-2026 | NRC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.6 M | 35.2 M | 40 M | 46.5 M | 50.3 M | 42.7 M | 43 M | 35.3 M | 34.2 M | 31.2 M | 26.4 M | 28.3 M | 24.8 M | 22.7 M | 18.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 50.3 M | 18.7 M | 33.5 M |
Quarterly Operating Income National Research Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.74 M | 1.59 M | 8.6 M | - | 7.98 M | 8.86 M | 8.76 M | - | 9.96 M | 9.36 M | 9.02 M | - | 11.1 M | 11.5 M | 11.7 M | - | 13.1 M | 12.2 M | 12 M | - | 12 M | 9.28 M | 11.2 M | - | 10.2 M | 10.1 M | 10.7 M | - | 9.17 M | 7.76 M | 8.96 M | - | 7.12 M | 8.45 M | 9.98 M | - | 7.34 M | 7.02 M | 8.01 M | - | 6.55 M | 6.36 M | 5.83 M | - | 7.16 M | 6.32 M | 8.4 M | - | 6.03 M | 5.53 M | 7.22 M | - | 5.65 M | 5.22 M | 6.08 M | - | 4.19 M | 3.83 M | 5.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 M | 1.59 M | 8.24 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 12.28 | -2.69 % | $ 99.4 M |  Israel |
 |
Agilent Technologies
A
|
1.35 B | $ 115.35 | -2.33 % | $ 35.1 B |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 22.48 | -1.58 % | $ 234 M |  China |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.81 | -2.7 % | $ 91.2 K | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Bioventus
BVS
|
54 M | $ 8.45 | -7.14 % | $ 563 M | USA |
 |
Celcuity
CELC
|
-113 M | $ 114.85 | -0.34 % | $ 4.53 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 175.23 | -3.37 % | $ 8.69 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 27.23 | -2.44 % | $ 756 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.59 | 2.41 % | $ 441 M | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 18.61 | 17.37 % | $ 2.41 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.11 | -1.36 % | $ 1.41 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 199.8 | -2.07 % | $ 22.2 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 195.75 | -2.99 % | $ 140 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 103.5 | 0.17 % | $ 19.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 9.69 | -3.0 % | $ 275 M | Israel |
 |
IDEXX Laboratories
IDXX
|
1.36 B | $ 607.19 | -1.9 % | $ 48.8 B | USA |
 |
DexCom
DXCM
|
912 M | $ 68.5 | -3.1 % | $ 26.7 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 124.76 | -2.71 % | $ 19.8 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 175.33 | -1.8 % | $ 30.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 107.08 | -3.19 % | $ 8.83 B |  Irlanda |
 |
Lantheus Holdings
LNTH
|
311 M | $ 72.86 | -4.53 % | $ 4.92 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.91 | -4.48 % | $ 954 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 269.52 | -2.34 % | $ 22.4 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 91.56 | -1.1 % | $ 11.5 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
-387 M | $ 5.15 | 0.29 % | $ 477 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.92 | -2.3 % | $ 1.14 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Natera
NTRA
|
-541 M | $ 196.94 | -0.1 % | $ 19.4 B | USA |